The reintroduction of radiotherapy into the integrated management of kidney cancer

Research output: Contribution to journalReview articlepeer-review

Abstract

The incidence of renal cell carcinoma (RCC) has been increasing, with a moderate subgroup of individuals who later develop metastatic disease. Historically, metastatic RCC has been managed with systemic therapy because RCC was believed to be radioresistant. Local therapies, such as stereotactic body radiation therapy, also known as stereotactic ablative radiotherapy, which utilize focused high-dose-rate radiation delivered over a limited number of treatments, have been successful in controlling local disease and, in some cases, extending survival in patients with intracranial and extracranial metastatic RCC. Stereotactic ablative radiotherapy is highly effective in treating intact disease when patients are not surgical candidates. Stereotactic ablative radiotherapy is well tolerated when used in conjunction with systemic therapy such as tyrosine kinase inhibitors and immune checkpoint inhibitors. These successes have prompted investigators to evaluate the efficacy of stereotactic body radiation therapy in novel settings such as neoadjuvant treatment of advanced RCC with tumor thrombus and oligometastatic/oligoprogressive disease states.

Original languageEnglish (US)
Pages (from-to)448-459
Number of pages12
JournalCancer Journal
Volume26
Issue number5
DOIs
StatePublished - Sep 1 2020

Keywords

  • Checkpoint inhibitors
  • intact kidney
  • metastatic renal cell carcinoma
  • renal cell carcinoma
  • stereotactic ablative radiotherapy
  • stereotactic body radiation therapy
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The reintroduction of radiotherapy into the integrated management of kidney cancer'. Together they form a unique fingerprint.

Cite this